http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0126650-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_74bc7827f551583c0e5d9d755f0cbf66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1967e3e31da100d0f169d02c23d23be0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3082bdc3c9967d59703f4fd64438cdd8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8366782f91765010cb631c996da4d535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_76d076dcbf634a56e73ba75c76775393
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ab16436aa28a250a739ebc668f8b779d
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365
filingDate 2000-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c65142b3ba61f8278a0b3ef82794cd5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32a145b9792715c15e0d103dd5ae36e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9145755342d9803a08d15d0948ea683e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b62771f6510b47c5a4291981f226b155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20e28102c813c16c4c9d43793d7d1e0a
publicationDate 2001-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-0126650-A3
titleOfInvention Use of n-acyl homoserine lactones for the treatment of cardiac tachyarrhythmias, ischaemic heart disease or congestive heart failure
abstract Compounds of formula (1) wherein n is 2 or 3, Y is O, S or NH; X is O, S or NH; and R is a 3-15C substituted aliphatic acyl group are useful as medicaments in the treatment or prevention of cardiac tachyarrythmias, ischaemic heart disease and congestive heart failure in human and non-human animals. Preferred compounds of the formula (1) include those in which R is a substituted alkylcarbonyl group in which the substituted alkyl has from 9 to 14 carbon atoms and is substituted at position β to the carbonyl by an oxo or a hydroxy group.
priorityDate 1999-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9640746-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9218614-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9501175-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0925786-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397310
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457814461

Total number of triples: 30.